Skip to content
value.today

Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. is listed today as Intelligent Bio Solutions Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Intelligent Bio Solutions Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$5 MPrivate placement after listing$2 to $10 million

Intelligent Bio Solutions Inc.: Private sale, Aug 2026

Investors in this round

1 investor had bought by the notice of Sep 14, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Intelligent Bio Solutions Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$399,999
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Simeonidis · Executive Officer · Chief Executive Officer
  • Spiro Sakiris · Executive Officer · Chief Financial Officer
  • Jason Isenberg · Director · Director
  • Jonathan Hurd · Director · Director
  • Nicola Fraser · Director · Director
  • Steven Boyages · Director · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co. Inc. (CRD 505) · New York, New YorkSold in IL

Remarks in the notice

  • On fees: “Ladenburg received $399,999.83 in commission, a $49,999.98 management fee, $60,000 expense reimbursement, and warrants for 101,832 shares of common stock. Ladenburg also receives 9% commission on gross proceeds from Series N-1 and N-2 Warrant exercises.”
  • On the amounts: “Offering closed September 2, 2026”

Signed by Spiro Sakiris, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 14, 2026. Read the notice at the SEC.

equity, optionsSEC
Dec 2025$10 MPrivate placement after listing$2 to $10 million

Intelligent Bio Solutions Inc.: Private sale, Dec 2025

Investors in this round

2 investors had bought by the notice of Jan 13, 2026: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Intelligent Bio Solutions Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$899,999
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Simeonidis · Executive Officer · Chief Executive Officer
  • Spiro Sakiris · Executive Officer · Chief Financial Officer
  • Jason Isenberg · Director
  • Jonathan Hurd · Director
  • Nicola Fraser · Director
  • Steven Boyages · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co. Inc. (CRD 505) · New York, New YorkSold in IL, NY

Remarks in the notice

  • On fees: “Ladenburg also received reimbursement of expenses of $65,000 and will receive a cash fee equal to 9.0% of the gross proceeds received by the Company from the cash exercise of any Series K-1 Warrants and Series K-2 Warrants.”
  • On the amounts: “The offering closed on January 2, 2026.”

Signed by Spiro Sakiris, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 13, 2026. Read the notice at the SEC.

equity, optionsSEC
Jul 2025$4 MPrivate placement after listing$2 to $10 million

Intelligent Bio Solutions Inc.: Private sale, Jul 2025

Investors in this round

7 investors had bought by the notice of Aug 11, 2025: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Intelligent Bio Solutions Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$345,542
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Simeonidis · Executive Officer · Chief Executive Officer
  • Spiro Sakiris · Executive Officer · Chief Financial Officer
  • Jason Isenberg · Director
  • Jonathan Hurd · Director
  • Nicola Fraser · Director
  • Steven Boyages · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co. Inc. (CRD 000000505) · New York, New YorkSold in IL, NV, NY, PA, TX

Remarks in the notice

  • On fees: “In addition to the cash fees, the placement agent also received warrants to purchase 101,160 shares of common stock at an exercise price of $2.375 per share.”
  • On the amounts: “Proceeds from warrant exercises & pre-payments per Inducement Ltr. Agmts. Series J Warrants for up to 4,046,456 shares issued in private placement. Up to $7,688,266 from future J Warrant exercises (if any) excluded; exercisable after stockholder approval.”

Signed by Spiro Sakiris, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 11, 2025. Read the notice at the SEC.

optionsSEC
Mar 2024$10 MPrivate placement after listing$10 to $50 million

Intelligent Bio Solutions Inc.: Private sale, Mar 2024

Investors in this round

8 investors had bought by the notice of Mar 22, 2024: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Intelligent Bio Solutions Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$910,455
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Simeonidis · Executive Officer · Chief Executive Officer
  • Spiro Sakiris · Executive Officer · Chief Financial Officer
  • Christopher Towers · Director
  • Jason Isenberg · Director
  • Jonathan Hurd · Director
  • Lawrence Fisher · Director
  • Steven Boyages · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co. Inc. (CRD 505) · New York, New YorkSold in CA, CT, FL, IL, MA, MD, MN, NJ, NY, TX

Remarks in the notice

  • On fees: “Ladenburg also received common stock warrants for 5% of shares and pre-funded warrants sold (exercise price of 125% of offering price per share & expiration of 5 yrs. from issuance) and reimbursement expenses of $65,000.”
  • On the amounts: “The offering closed on March 12, 2024.”

Signed by Spiro Sakiris, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 22, 2024. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Intelligent Bio Solutions Inc., its revenue in fiscal 2026 came from these product and service lines: Sales of Goods - Cartidges $2.49 million (59%), Sales of Goods - Readers $900,000 (21%), Other sales - accessories $830,000 (20%).

    Annual report (SEC XBRL) · Jun 2026

  • Intelligent Bio Solutions Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Sep 2026

Products and services#

No products or services of Intelligent Bio Solutions Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Intelligent Bio Solutions Inc.
InvestorKindAmountRoundRoleSource
Spiro Kevin SakirisPersonnot statednot statedHeld Series A preferred stock (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Intelligent Bio Solutions Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Intelligent Bio Solutions Inc.
NameRoleNamed in
Harry SimeonidisChief Executive OfficerSep 2026
Spiro SakirisChief Financial OfficerSep 2026
Jason IsenbergDirectorSep 2026
Jonathan HurdDirectorSep 2026
Nicola FraserDirectorSep 2026
Steven BoyagesDirectorSep 2026
Christopher TowersDirectorMar 2024
Lawrence FisherDirectorMar 2024

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.